To Our Fellow Shareholders,
As Chief Executive Officer I want to extend our appreciation for all your support and thoughtfulness during this very sad and sudden transition after the passing of Clarence Smith. As friends and shareholders, you are the strength we rely on as we sustain and advance the vision that Clarence Smith established in his tenure leading the company.
Our commitment to developing the market for our unique AAGP (PKX-001) molecule remains firm and supported by the executive team and our partners. The extremely robust molecule is a first-in-class, synthetic glycopeptide with established safety and efficacy in pre-clinical and clinical studies. The molecule is a workhorse that delivers cell protection and helps to control inflammation, in ways that can greatly improve cell therapy strategies and many other disease treatment applications.
Protokinetix Inc. holds a stable patent portfolio that protects these unique applications worldwide, including the United States, Europe, UK, Asia and beyond.
Through our current outreach program we have garnered the attention of pharmaceutical companies of various sizes with active market applications with interest to incorporate our glycopeptide in their strategies to address Type 1 Diabetes, cell therapy enhancement, dry-eye and other ophthalmological or topical disorders.
During this season of thanksgiving, I want to express my sincere gratitude to you directly. Your continued support makes our company’s accomplishments possible and allows us to continue down the path to gaining market traction and deliver for you, our shareholders, as Clarence Smith committed to doing. Let us go forward together in fond memory of our friend.
Mike G
Michael R. Guzzetta
Chief Executive Officer
Protokinetix Inc.
About ProtoKinetix, Incorporated
For further information, please contact:
Michael Guzzetta
President, CEO & CFO
Telephone: 330-445-4971
Email: [email protected]
Twitter: @ProtoKinetix
